Engimata is honored to present its research titled "A Versatile Room Temperature Stable Lipid Nanoparticle COVID-19 Protein-Based Vaccine." Join us on Monday, October 23, 2023, from 3:30 PM – 4:30 PM ET at Poster Number: M1530-02-08.
Special Note: Our poster has also been chosen for a unique collection and will have an additional presentation on Oct 24th.
Date: Oct 22-24, 2023 Location: Virtual Presentation (Main event in Switzerland)
Engimata's research on our lipid nanoparticle COVID-19 vaccine has been accepted for virtual presentation at the International Society for Vaccines (ISV) Congress.
Engimata is an early stage biopharma company located in the San Francisco Bay Area. Engimata has developed a COVID-19 vaccine, using its platform nano lipid particle technology with recombinant viral surface proteins to mimic those found on the SARS-CoV-2 coronavirus particle.
